
维百奥生物可提供Polymun Scientific品牌产品
【声明1】我司本网页所展示产品列表、Logo、图片、商标、品牌中英文名字,仅作为客观展示产品所用,如有侵权,请联系随时联系我司。
【声明2】我司不销售归类为危险品或其他违规品的产品,但由于本行业产品货号、型号众多,我司在发布时,难免遗漏,如在网页上显示某一货号或品名属于危险品或其他违规品,不代表我司倾向宣传或有意愿销售该产品;欢迎各界朋友批评指正,我们将立即改正。
【声明3】本网页所展示的品牌和产品,仅用于科学研究,不可用于人体、不可用于诊断或治疗。
Polymun Scientific是生物制药CRO及药物递送技术公司,主要提供脂质体/LNP制剂开发服务和哺乳动物细胞技术平台。Polymun的两大核心能力是利用哺乳动物细胞技术开发和生产生物制药,以及创新的脂质体/LNP药物递送平台。Polymun将该递送平台应用于mRNA、小分子、肽及蛋白质等多种药用活性成分,优化药理学活性制剂的递送效果;提供从研发到生产的全流程CRO服务及技术授权服务,支持客户项目的工业放大与成本控制。公司拥有约100名高素质科学家、技术人员及支持人员,其中50%拥有生物技术、生物学或化学等自然科学领域的学术头衔。Polymun致力于以质量和可靠性为前提,推动创新与创造力,产品与服务广泛应用于生物制药开发、基因治疗、疫苗研发及靶向药物递送等领域。

❑ Polymun Scientific产品线
● 生物制药:提供rhFSH(生物类似药)、红细胞生成素(生物类似药)、HIV包膜蛋白、SGM-101抗体、人源化抗Netrin-1单克隆抗体、人源化单克隆IgG4及小鼠单克隆抗体HPC-4,覆盖生物类似药开发、传染病研究与肿瘤靶向治疗等领域。
● 脂质体/LNP药物制剂:涵盖编码花生过敏原的mRNA脂质纳米颗粒制剂、编码III型干扰素(ETH47)mRNA的脂质纳米颗粒制剂、Omega表观基因组控制(OEC)mRNA药物、mRNA脂质纳米颗粒制剂及脂质体佐剂WTCc,支持疫苗开发、免疫治疗与基因药物递送研究。
● 研发项目:包括脂质体超氧化物变异酶、重组猪胰蛋白酶、碳酰化Epo-Fc融合蛋白及HIV抗体,专注于酶替代疗法、生物制药工艺优化及传染病防治的前沿探索。
● 研究试剂:提供HIV抗体与HIV抗原,用于传染病免疫检测、疫苗研发及基础科研中的抗原抗体分析。
❑ Polymun Scientific产品列表
| 分类 | 产品名称 |
| Biopharmaceuticals | rhFSH (biosimilar), for in-vitro fertilization |
| Biopharmaceuticals | Erythropoietin (biosimilar), stimulation of production of reticulocytes |
| Biopharmaceuticals | HIV envelope protein as self-assembling nanoparticles, HIV vaccine candidate |
| Biopharmaceuticals | Two trimeric HIV envelope proteins established by University of Regensburg, HIV vaccine candidates |
| Biopharmaceuticals | Recombinant human soluble angiotensin converting enzyme 2 (ACE2), therapy of COVID-19 as well as various diseases with an imbalance of the renin angiotensin system |
| Biopharmaceuticals | SGM-101, antibody conjugated to near-infrared fluorochrome, detection of cancer during surgery for colorectal cancer or pancreatic cancer |
| Biopharmaceuticals | Eight trimeric HIV envelope proteins, HIV vaccine |
| Biopharmaceuticals | Humanised anti-Netrin-1 monoclonal antibody, treatment of cancer |
| Biopharmaceuticals | GNbAC1, humanized monoclonal IgG4, treatment of multiple sclerosis |
| Biopharmaceuticals | Human monoclonal IgG1, treatment of Hepatitis C virus (HCV) infection |
| Biopharmaceuticals | Murine monoclonal antibody HPC-4, affinity purification of protein C (Ceprotin®) |
| Biopharmaceuticals | Chimeric monoclonal IgG1 against GD2, treatment of neuroblastoma |
| Liposomal/LNP | Lipid nanoparticle formulation of mRNA coding for type III interferon (ETH47) |
| Liposomal/LNP | Saponin/MPLA nanoparticles (SMNP) developed at the Koch Institute for Integrative Cancer Research at Massachusetts Institute of Technology (MIT) as adjuvant for HIV candidate vaccines |
| Liposomal/LNP | Omega Epigenomic Controller (OEC) mRNA medicine delivered by lipid nanoparticles (OTX-2002) |
| Liposomal/LNP | Lipid nanoparticle formulation of mRNA coding for Plasmodium falciparum (causative pathogen for Malaria) antigens |
| Liposomal/LNP | Lipid nanoparticle formulation of mRNA coding for Mycobacterium tuberculosis antigens |
| Liposomal/LNP | Lipid nanoparticle formulation of mRNA coding for HSV-2 antigens |
| Liposomal/LNP | Lipid nanoparticle formulation of mRNA as coronavirus vaccine |
| Liposomal/LNP | Lipid nanoparticle formulation of surface protein encoding mRNA as coronavirus vaccine |
| Liposomal/LNP | Lipid nanoparticle formulations of surface protein encoding mRNA and self-amplifying RNA as coronavirus vaccine |
| Liposomal/LNP | Plain liposomes as carrier for mRNA for cell therapy |
| Liposomal/LNP | Lipid nanoparticle formulation of mRNA coding for a therapeutic antibody |
| Liposomal/LNP | Liposomal formulation of curcumin for the treatment of cancer |
| Liposomal/LNP | Lipid nanoparticle formulation of self-amplifying RNA as coronavirus vaccine |
| Liposomal/LNP | Lipid nanoparticle formulation of miRNA INT-1B3 for treatment of advanced solid tumors |
| Liposomal/LNP | Liposomal saRNA MTL-CEBPA with Smarticle technology for cancer treatment |
| Liposomal/LNP | Liposomal miRNA MRX34 with Smarticle technology for cancer treatment |
| Liposomal/LNP | Liposomal formulation of siRNA |
| Liposomal/LNP | Liposomal adjuvant WTCc |
| Liposomal/LNP | ACI-24, liposomal Alzheimer’s disease vaccine with MPLA adjuvant |
| Liposomal/LNP | Liposomal formulation of HIV membrane protein gp41 and MPLA as HIV vaccine |
| Liposomal/LNP | Liposomal of DNAi PNT100 with Smarticle technology for cancer treatment |
| Liposomal/LNP | Liposomal formulation of galantamine for the treatment of neuropathic pain |